Phase I study assessing a two-consecutive-day (QD x 2) dosing schedule of the HSP90 inhibitor, AT13387, in patients with advanced solid tumors

被引：0
|
作者：
Khanh Tu Do
Speranza, Giovanna
Chen, Alice P.
Trepel, Jane B.
Lee, Min-Jung
Lee, Sunmin
Phillips, Larry
Collins, Jerry M.
Weil, Marcie K.
Kinders, Robert J.
Khin, Sonny
Allen, Deborah
Parthasarathy, Ramya
Doroshow, James H.
Kummar, Shivaani
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA
[3] NIH, Bethesda, MD 20892 USA
[4] NCI, Rockville, MD USA
[5] SAIC Frederick, Frederick, MD USA
[6] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
[7] NCI, Div Canc Treatment & Diag, Bethesda, MD 20892 USA
[8] NCI, Dev Therapeut Clin, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3087
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors
    Khanh Do
    Speranza, Giovanna
    Chang, Lun-Ching
    Polley, Eric C.
    Bishop, Rachel
    Zhu, Weimin
    Trepel, Jane B.
    Lee, Sunmin
    Lee, Min-Jung
    Kinders, Robert J.
    Phillips, Larry
    Collins, Jerry
    Lyons, John
    Jeong, Woondong
    Antony, Ramya
    Chen, Alice P.
    Neckers, Len
    Doroshow, James H.
    Kummar, Shivaani
    [J]. INVESTIGATIONAL NEW DRUGS, 2015, 33 (04) : 921 - 930
  • [2] Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors
    Khanh Do
    Giovanna Speranza
    Lun-Ching Chang
    Eric C. Polley
    Rachel Bishop
    Weimin Zhu
    Jane B. Trepel
    Sunmin Lee
    Min-Jung Lee
    Robert J. Kinders
    Larry Phillips
    Jerry Collins
    John Lyons
    Woondong Jeong
    Ramya Antony
    Alice P. Chen
    Len Neckers
    James H. Doroshow
    Shivaani Kummar
    [J]. Investigational New Drugs, 2015, 33 : 921 - 930
  • [3] First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
    Shapiro, Geoffrey I.
    Kwak, Eunice
    Dezube, Bruce J.
    Yule, Murray
    Ayrton, John
    Lyons, John
    Mahadevan, Daruka
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (01) : 87 - 97
  • [4] Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer
    Williams, Nicole O.
    Quiroga, Dionisia
    Johnson, Courtney
    Brufsky, Adam
    Chambers, Mara
    Bhattacharya, Saveri
    Patterson, Maria
    Sardesai, Sagar D.
    Stover, Daniel
    Lustberg, Maryam
    Noonan, Anne M.
    Cherian, Mathew
    Bystry, Darlene M.
    Hill, Kasey L.
    Chen, Min
    Phelps, Mitch A.
    Grever, Michael
    Stephens, Julie A.
    Ramaswamy, Bhuvaneswari
    Carson III, William E.
    Wesolowski, Robert
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [5] Re: First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors Editorial Comment
    Chang, Sam S.
    [J]. JOURNAL OF UROLOGY, 2016, 196 (01): : 61 - 61
  • [6] Phase I pharmacokinetic and pharmacodynamic study of the heat shock protein 90 inhibitor AT13387 in patients with refractory solid tumors.
    Shapiro, G.
    Kwak, E. L.
    Dezube, B. J.
    Lawrence, D. P.
    Cleary, J. M.
    Lewis, S.
    Squires, M.
    Lock, V.
    Lyons, J. F.
    Yule, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Design and validation of pharmacodynamic assays to measure the activity of the HSP90 inhibitor, AT13387 in surrogate tissue and tumor in a phase I study
    Lyons, J.
    Squires, M.
    Lock, V.
    Graham, B.
    Smyth, T.
    Ong, E.
    Mahadevan, D.
    Kwak, E.
    Shapiro, G.
    [J]. EJC SUPPLEMENTS, 2010, 8 (07): : 187 - 187
  • [8] First-in-human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors
    Mahadevan, Daruka
    Rensvold, Diane M.
    Kurtin, Sandra E.
    Cleary, James M.
    Gandhi, Leena
    Lyons, John F.
    Lock, Victoria
    Lewis, Samantha
    Shapiro, Geoffrey
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] A phase I study of Debio 0932, an oral HSP90 inhibitor, in patients with solid tumors
    Isambert, Nicolas
    Hollebecque, Antoine
    Berge, Yann
    van Ingen, Hein
    Brienza, Silvano
    Destaillats, Alice
    Soria, Jean-Charles
    Fumoleau, Pierre
    Delord, Jean-Pierre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Jones, Suzanne F.
    Hart, Lowell
    Pant, Shubham
    Moyhuddin, Adil
    Lane, Cassie M.
    Earwood, Chris
    Murphy, Patrick
    Patton, Jeffrey
    Penley, William C.
    Thompson, Dana
    Infante, Jeffrey R.
    [J]. CANCER INVESTIGATION, 2015, 33 (10) : 477 - 482
12345